Prestige Consumer Healthcare trades at a forward P/E of 9.3x with analyst upside of 25% and strong operating margins of 17%, but has missed earnings estimates in all 4 of the last 4 quarters with estimates trending downward — making the value case dependent on a fundamental turnaround that has not yet materialized.
Thesis pillars
- Valuation Discount Vs Quality→Stable
- Margin Quality Floor Support→Stable
- Earnings Miss Streak Resolution→Stable
- +1 more pillar — see the Why tab for full reasoning
Prestige Consumer Healthcare In (PBH) Stock Analysis
Recovery setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Multiple concerning factors at $52.26: Consecutive earnings misses (3); Leverage penalty (D/E 1.1): -0.5.
Prestige Consumer Healthcare markets OTC health and personal care brands—including Monistat, Dramamine, Clear Eyes, and Fleet—across North America (83.9% of fiscal 2026 revenues) and internationally. Walmart (~20%) and Amazon (~15%) were the only customers exceeding 10% of... Read more
Sell if holding. Multiple concerning factors at $52.26: Consecutive earnings misses (3); Leverage penalty (D/E 1.1): -0.5. Chart setup: Death cross but MACD improving, RSI 61. Score 5.4/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 60d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-09-06Recent Developments — Prestige Consumer Healthcare In
Latest news
- NEWS Prestige Consumer Healthcare Inc (PBH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey — TradingKey neutral
- NEWS Prestige Consumer Healthcare Inc (PBH) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com — tradingkey.com neutral
- NEWS Prestige Consumer Healthcare (PBH) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance — Yahoo Finance neutral
- NEWS Prestige Consumer Healthcare: Fiscal Q4 Earnings Snapshot - KING5.com — KING5.com neutral
- NEWS Prestige Consumer Healthcare: Fiscal Q4 Earnings Snapshot - kare11.com — kare11.com neutral
Generated 2026-09-06T05:26:55Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWCustomerWalmart20%10-K Item 1: 'Walmart accounted for approximately 20%, 19% and 20%, respectively, of our gross revenues'
- LOWCustomerAmazon15%10-K Item 1: 'Amazon accounted for approximately 15%, 14%, and 11%, respectively, of our gross revenues'
- LOWSupplierprivately owned pharmaceutical manufacturer21%10-K Item 1A: 'a privately owned pharmaceutical manufacturer...This manufacturer accounted for approximately 21%, respectively, of our gross revenues in 2026 and 2025'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $52.26: Consecutive earnings misses (3); Leverage penalty (D/E 1.1): -0.5. Chart setup: Death cross but MACD improving, RSI 61. Prior stop was $49.42. Score 5.4/10, moderate confidence.
Take-profit target: $58.99 (+12.9% upside). Prior stop was $49.42. Stop-loss: $49.42.
Leverage penalty (D/E 1.1): -0.5; Consecutive earnings misses (3); Weak growth.
Prestige Consumer Healthcare In trades at a P/E of 14.7 (forward 10.3). TrendMatrix value score: 6.8/10. Verdict: Sell.
10 analysts cover PBH with a consensus score of 4.0/5. Average price target: $68.
What does Prestige Consumer Healthcare In do?Prestige Consumer Healthcare markets OTC health and personal care brands—including Monistat, Dramamine, Clear Eyes, and...
Prestige Consumer Healthcare markets OTC health and personal care brands—including Monistat, Dramamine, Clear Eyes, and Fleet—across North America (83.9% of fiscal 2026 revenues) and internationally. Walmart (~20%) and Amazon (~15%) were the only customers exceeding 10% of fiscal 2026 gross revenues. The company outsources most manufacturing to 95 third-party contractors while operating three owned facilities in the U.S., Canada, and Australia.